Biotech News

Olema Oncology Reports Third Quarter 2026 Financial and Operating Results

Olema Pharmaceuticals, Inc. (OLMA)Olema Pharmaceuticals, Inc.Earnings

On track to announce top-line data from the pivotal Phase 3 OPERA-01 trial in the first quarter of 2027 Continued strong enrollment in the pivotal Phase 3 OPERA-02 trial and the Phase 1b/2 study of OP-3136 Appointed Jason O’Byrne, MBA, as Chief Financial Officer Ended the third quarter with $413.8

Related news

Olema Pharmaceuticals, Inc.

Endocrine-Driven Cancer Company Olema Oncology develops targeted therapies based on estrogen receptor biology, nuclear receptors, and resistance mechanisms in breast cancer. Palazestrant Palazestrant is an oral complete estrogen receptor antagonist being studied as monotherapy and in combinations for ER-positive, HER2-negative breast...

Recent company news

Stock data

Close
7.15 USD
Market cap
933.74M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States